Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban.

S A Mousa1, J M Bozarth, U P Naik

  • 1DuPont Pharmaceuticals Company, Wilmington, Delaware 19880-0400, USA. shaker.a.mousa@dupontpharma.com

British Journal of Pharmacology
|May 26, 2001
PubMed
Summary

Roxifiban active form exhibits superior platelet binding affinity compared to other RGD mimetics. This distinct profile, with high affinity and slow dissociation, may influence its pharmacodynamics and pharmacokinetics.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Malnutrition and cachexia are associated with poor CAR T-cell therapy outcomes including survival.

Clinical nutrition ESPEN·2024
Same author

Sarcopenic Obesity and Depression: A Systematic Review.

The Journal of frailty & aging·2022
Same author

Lycopene nanoparticles promotes osteoblastogenesis and inhibits adipogenesis of rat bone marrow mesenchymal stem cells.

European review for medical and pharmacological sciences·2021
Same author

[Rose-scented geranium essential oil from Algeria (Pelargonium graveolens L'Hérit.): Assessment of antioxidant, anti-inflammatory and anticancer properties against different metastatic cancer cell lines].

Annales pharmaceutiques francaises·2021
Same author

Avoiding COVID-19 complications with diabetic patients could be achieved by multi-dose Bacillus Calmette-Guérin vaccine: a case study of beta cells regeneration.

Die Pharmazie·2020

Area of Science:

  • Pharmacology
  • Biochemistry
  • Medicinal Chemistry

Background:

  • Non-peptide orally active RGD mimetic prodrugs like Orbofiban and Roxifiban have entered clinical trials for their antiplatelet effects.
  • Understanding the binding profiles of these agents to platelet GPIIb/IIIa is crucial for their therapeutic development.

Purpose of the Study:

  • To compare the platelet GPIIb/IIIa binding profiles of the active forms of Roxifiban, Sibrafiban, SR121566, and Orbofiban.
  • To elucidate the structure-activity relationship within the Roxifiban series regarding platelet binding.

Main Methods:

  • Competitive binding assays using radiolabeled ligands (3H-Roxifiban active form (XV459), 3H-DMP728, 125I-Echistatin, 125I-Fibrinogen).
  • Confocal microscopy to assess binding interactions with FITC-labeled GPIIb/IIIa antagonist cyclic RGD peptidomimetic (XL086).

Related Experiment Videos

Main Results:

  • All tested RGD mimetics bind to the same site(s) on human platelets, as shown by competitive inhibition.
  • Roxifiban active form (XV459) demonstrated the highest potency in inhibiting ligand binding to human platelets.
  • Structure-activity relationship studies indicated a specific substituent in Roxifiban contributes to high-affinity binding and slow dissociation.

Conclusions:

  • Roxifiban active form exhibits a distinct binding profile characterized by high affinity to both activated and resting platelets and a slow dissociation rate (K(off)).
  • These unique binding characteristics of Roxifiban may differentiate its pharmacodynamic and pharmacokinetic properties from other GPIIb/IIIa antagonists.